Creating a Path Forward: Diverse Representation in Clinical Trials for Alzheimer’s Disease
Peggye Dilworth-Anderson, PhD
Professor, Dept of Health Policy and Management
University of North Carolina-Chapel Hill
James E. Galvin, MD, MPH
Professor of Neurology
University of Miami
Victor Narcisse, MD, FACP
Associate Division Head, Hospital Medicine
Houston Methodist Hospital
|Credit Provided by||Rush University|
|Funding Statement||Earn complimentary CME credit.|
|Copyright Statement with Logo||Home Office
Alzheimer's Association National Office, 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601
Alzheimer's Association is a not-for-profit 501(c)(3) organization.
© 2021 Alzheimer’s Association®. All rights reserved.
All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies and Standards for Commercial Support. Recommendations involving clinical medicine in a Continuing Medical Education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis.
This CME/CE activity might describe the off-label, investigational or experimental use of medications that may exceed their FDA- approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. RUSH University Medical Center requires the speaker to disclose that a product is not labeled for the use under discussion.
|Target Audience / Intended Audience||This activity is intended for primary care clinicians including internists, family physicians, nurse practitioners, and physician assistants as well as specialists who work with patients with cognitive impairment or dementia.|
|Statement of Need / Activity Purpose||
Clinical trial participation is low amongst diverse populations. The purpose of this course is so we to increase awareness on the importance of representation and provide clinicians with the tools and resources to effectively communicate around clinical trials and recruit their patients.
Upon completion of this webinar you will learn:
|Method of Participation||
This curriculum will take approximately 60 minutes to complete. To receive maximum credit, participants are required to view the presentation in its entirety. Upon completion of the activity and evaluation form, a certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact email@example.com.
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Rush University Medical Center designates enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity. This course has been approved for medical ethics.
Disclosures- Faculty reports the following relationship(s)
Individuals in control of content have disclosed the following:
James Galvin, MD, MPH – Consultant, Alpha-Cognition, Biogen, Cognivue, Eisai, Genentech, Roche
All of the relevant financial relationships listed for these individuals have been mitigated. The remaining course director(s), planner(s), faculty, and reviewer(s) of this activity have no relevant financial relationship(s) with ineligible companies to disclose.
|Hardware and Software Requirements||
Hardware and Software Requirements